Impact of Bacillus Clausii Administration on Irritable Bowel Syndrome Patients
Condition: Irritable Bowel Syndrome Interventions: Drug: Bacillus clausii; Drug: Trimebutine Sponsor: Hospital Britanico Completed
Conclusions: ELS-induced visceral pain and visceral hypersensitivity are associated with the underfunction of SK2 channels in the spinal DH. PMID: 33029124 [PubMed - in process]
Abstract The therapeutic value of specific fibres is partly dependent on their fermentation characteristics. Some fibres are rapidly degraded with generation of gases that induce symptoms in patients with irritable bowel syndrome (IBS), while more slowly- or non-fermentable fibres may be more suitable. More work is needed to profile a comprehensive range of fibre to determine suitability for IBS. Using a rapid in vitro fermentation model, gas production and metabolite profiles of a range of established and novel fibres were compared. Fibre substrates (n=15) were added to faecal slurries from 3 healthy donors for 4...
Authors: Adriani A, Saracco GM, Pellicano R PMID: 33016665 [PubMed - as supplied by publisher]
Conclusion: EA can regulate the P2X3 receptor protein and mRNA expression levels in the colon and related DRG of IBS rats with visceral pain and then regulate the excitatory properties of DRG neurons. PMID: 33014041 [PubMed]
CONCLUSIONS: We have demonstrated that administration of Lp299v in cancer patients receiving home enteral nutrition may improve laboratory parameters, predominantly the concentration of albumin, however, overall it does not have an impact on nutritional status. Lp299v may reduce the gastrointestinal symptoms related to enteral nutrition; notwithstanding, the improvement of quality of life may be the result of enteral nutrition rather than the effect of administration of Lp299v. PMID: 33015813 [PubMed - in process]
Clinical Outcome Assessments (COA) Qualification Submissions Office of Drug Evaluation (ODE) III Division of Gastroenterology and Inborn Error Products (DGIEP) DDT COA Number DDT COA #000005
Hello everyone! So, I am applying to medical school Spring 2021 for EY 2022. I have jumped back and forth regarding this question for a long time and would like to ask the SDN community. Jumping right in, I have IBD (Irritable Bowel Disease) and was diagnosed junior year of high school. I am now a senior in college and it has never really bothered me too much. I am lucky and grateful to have had an awesome physician who put me on a biologic that has put me into remission. So, how is... Discussing Chronic Illness and Applying to Medical School
Conclusion: In a c ohort of Greek FD patients, SIBO prevalence was similar to that of IBS subjects and higher compared to that of controls.
Authors: Chan D, Skidmore P, O'Brien L, Watson S, Gearry R Abstract AIMS: To investigate the feasibility and effectiveness of dietitian-led education on using the low fermentable oligosaccharide, disaccharide, monosaccharide and polyols (FODMAP) diet in adults with irritable bowel syndrome (IBS) in Christchurch, New Zealand. METHODS: Patients with IBS (n=25) were referred by their general practitioner to attend a group education programme. The number recruited and subsequent attendance were used to evaluate feasibility. The Structured Assessment of Gastrointestinal Symptoms (SAGIS) questionnaire and Hospital An...
Condition: Irritable Bowel Syndrome Intervention: Drug: lactobacillus delbruekii and lactobacillus fermentum) and itopride hcl Sponsor: Ain Shams University Completed
More News: Irritable Bowel Syndrome